About: COVID‐19 Pandemic: Challenges and Solutions from the Cardiology Pharmacist's Perspective

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID‐19 Pandemic: Challenges and Solutions from the Cardiology Pharmacist's Perspective Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID‐19 Pandemic: Challenges and Solutions from the Cardiology Pharmacist's Perspective
Creator	Boyd, Michael Jacobs, Joshua Zoubek, Bagnola, Barcelona, Robert Blais, Danielle Brink, Heidi Cardiology, Aaron Chilbert, Maya Fccp, Charles Galipeau, Daniel Gengler, Brooke Gerlach, Anthony Hayes, Kazmi, Hasan Lavelle, Rachel Lindsley, John Macaulay, Militello, Orzel, Patel, Sajni Pickworth, Kerry Simone, Pamela Tasca, Kristen Varnado,
Source	Medline; PMC
abstract	INTRODUCTION: The recent coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenges pharmacists worldwide. Alongside other specialized pharmacists, we re‐evaluated daily processes and therapies used to treat COVID‐19 patients within our institutions from a cardiovascular perspective and share what we have learned. OBJECTIVES: To develop a collaborative approach for cardiology issues and concerns in the care of confirmed or suspected COVID‐19 patients by drawing on the experiences of cardiology pharmacists across the country. METHODS: On March 26, 2020, a conference call was convened composed of 24 cardiology residency‐trained pharmacists (23 actively practicing in cardiology and 1 in critical care) from 16 institutions across the United States to discuss cardiology issues each have encountered with COVID‐19 patients. Discussion centered around providing optimal pharmaceutical care while limiting staff exposure. RESULTS: The collaborative of pharmacists found for the ST‐elevation myocardial infarction patient, many institutions were diverting COVID‐19 rule‐out patients to their Emergency Department (ED). Thrombolytics are an alternative to percutaneous coronary intervention (PCI) allowing for timely treatment of patients and decreased staff exposure. An emergency response grab and go kit includes initial drugs and airway equipment so the patient can be treated and the cart can be left outside the room. Cardiology pharmacists have developed policies and procedures to address monitoring of QT prolonging medications, the use of inhaled prostacyclins, and national drug shortages. Technology has allowed us to practice social distancing, while staying in close contact with our teams, patients, and colleagues and continuing to teach. Residents are engaged in unique decision‐making processes with their preceptors and assist as pharmacist extenders. CONCLUSION: Cardiology pharmacists are in a unique position to work with other pharmacists and health care professionals to implement safe and effective practice changes during the COVID‐19 pandemic. Ongoing monitoring and adjustments are necessary in rapidly changing times. This article is protected by copyright. All rights reserved.
has issue date	2020-07-17(xsd:dateTime)
bibo:doi	10.1002/jac5.1307
bibo:pmid	32838223
has license	no-cc
sha1sum (hex)	fa365dca722cc1df0690e2daa650c64f9f1f7ec3
schema:url	https://doi.org/10.1002/jac5.1307
resource representing a document's title	COVID‐19 Pandemic: Challenges and Solutions from the Cardiology Pharmacist's Perspective
has PubMed Central identifier	PMC7404851
has PubMed identifier	32838223
schema:publication	J Am Coll Clin Pharm
resource representing a document's body	covid:fa365dca722cc1df0690e2daa650c64f9f1f7ec3#body_text
is schema:about of	named entity 'processes' named entity 'perspective' named entity 'EVALUATED' named entity 'PERSPECTIVE' named entity 'INTRODUCTION' named entity 'CAUSED BY' named entity 'OUR' named entity 'COVID-19' named entity 'HAVE' named entity 'SPECIALIZED' named entity 'CHALLENGES' named entity 'DAILY' named entity 'worldwide' named entity 'treat' named entity 'coronavirus disease 2019' named entity 'Perspective' named entity 'COVID' named entity 'COVID' named entity 'Pharmacist' named entity 'defibrillation' named entity 'COVID-19 pandemic' named entity 'ICU' named entity 'remote learning' named entity 'amiodarone' named entity 'Reteplase' named entity 'unstable angina' named entity 'myocardium' named entity 'enoxaparin' named entity 'heart failure' named entity 'cardiology' named entity 'COVID' named entity 'patient care' named entity 'ischemic heart disease' named entity 'hydroxychloroquine' named entity 'aerosolization' named entity 'CCL' named entity 'SARS-CoV-2 virus' named entity 'CCL' named entity 'medical intensive care unit' named entity 'intubated' named entity 'CCL' named entity 'American College of Cardiology' named entity 'epinephrine' named entity 'ischemia' named entity 'thrombolytics' named entity 'COVID-19' named entity 'Primary percutaneous coronary intervention' named entity 'diuretics' named entity 'enoxaparin' named entity 'COVID-19' named entity 'GP IIb/IIIa' named entity 'social distancing' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'circulatory support' named entity 'UFH' named entity 'pulmonary artery' named entity 'pharmacist'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software